Neurofilaments in multiple sclerosis
When evaluated at 3 or 12 months, serum neurofilament light chain (sNfL) levels were predictive of new or enlarging T2 lesions in patients with multiple sclerosis (MS) regardless of treatment assignment, new sub-study data from the ASCLEPIOS I/II trials showed.